3248 Results for "

dual oxidase 2

" in MedChemExpress (MCE) Product Catalog:
Products (3248)

3248 Results for "dual oxidase 2" in MCE Product Catalog:

860
860 Publications Verification
Cat. No.: HY-18739
CAS No.: 16561-29-8
Synonyms: PMA; TPA; Phorbol myristate acetate
Phorbol 12-myristate 13-acetate (PMA; TPA; Phorbol myristate acetate), a phorbol ester, is a dual SphK and protein kinase C (PKC) activator [2]. Phorbol 12-myristate 13-acetate is a NF-κB activator. Phorbol 12-myristate 13-acetate induces differentiation in THP-1 cells (Validated by MedChemExpress) .
loading...
    loading...
183
183 Cited Publications
Cat. No.: HY-10181A
CAS No.: 854001-07-3
Purity:  98.86%
Synonyms: BMS-354825 hydrochloride
Research Areas:  

Cancer

Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib hydrochloride also induces apoptosis and autophagy.
loading...
    loading...
183
183 Cited Publications
Cat. No.: HY-10181B
CAS No.: 863127-77-9
Purity:  99.58%
Synonyms: BMS-354825 monohydrate
Research Areas:  

Cancer

Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib monohydrate also induces apoptosis and autophagy.
loading...
    loading...
183
183 Cited Publications
Cat. No.: HY-10181
CAS No.: 302962-49-8
Purity:  99.83%
Synonyms: BMS-354825
Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy, and can cross the blood-brain barrier [2].
loading...
    loading...
153
153 Cited Publications
Cat. No.: HY-12708
CAS No.: 50-53-3
Purity:  99.75%
Chlorpromazine is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine also can inhibit clathrin-mediated endocytosis [2] .
loading...
    loading...
153
153 Cited Publications
Cat. No.: HY-B0407A
CAS No.: 69-09-0
Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis [2] .
loading...
    loading...
113
113 Cited Publications
Cat. No.: HY-10261
CAS No.: 850140-72-6
Purity:  99.92%
Synonyms: BIBW 2992
Research Areas:  

Cancer

Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer [2] .
loading...
    loading...
113
113 Cited Publications
Cat. No.: HY-10261A
CAS No.: 850140-73-7
Purity:  99.74%
Synonyms: BIBW 2992MA2
Research Areas:  

Cancer

Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer [2] .
loading...
    loading...
89
89 Cited Publications
Cat. No.: HY-50878A
CAS No.: 1415560-69-8
Synonyms: PF-02341066 hydrochloride
Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition [2] .
loading...
    loading...
80
80 Cited Publications
Cat. No.: HY-18950
CAS No.: 1415925-18-6
GSK2795039 is a NADPH oxidase 2 (NOX2) inhibitor with a mean pIC50 of 6 in different cell-free assays. GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption . GSK2795039 reduces apoptosis [2].
loading...
    loading...
71
71 Cited Publications
Cat. No.: HY-15174
CAS No.: 1028385-32-1
Purity:  99.87%
Synonyms: BEZ235 Tosylate; NVP-BEZ 235 Tosylate
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.
loading...
    loading...
71
71 Cited Publications
Cat. No.: HY-50673
CAS No.: 915019-65-7
Synonyms: BEZ235; NVP-BEZ235
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC50s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.
loading...
    loading...
67
67 Cited Publications
Cat. No.: HY-50673A
CAS No.: 2319647-83-9
Synonyms: BEZ235 hydrochloride; NVP-BEZ235 hydrochloride
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Dactolisib (BEZ235) hydrochloride is an orally active, dual pan-class I PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR with IC50 of 4 nM/5 nM/7 nM/75 nM and 20.7 nM, respectively. Dactolisib hydrochloride (BEZ235) inhibits mTORC1 and mTORC2 .
loading...
    loading...
66
66 Cited Publications
Cat. No.: HY-100965
CAS No.: 4673-26-1
Purity:  99.91%
Synonyms: DPI
Diphenyleneiodonium chloride is a NADPH oxidase (NOX) inhibitor and also functions as a TRPA1 activator with an EC50 of 1 to 3 μM. Diphenyleneiodonium chloride selectively inhibits intracellular reactive oxygen species.
loading...
    loading...
65
65 Cited Publications
Cat. No.: HY-15648F
CAS No.: 1797983-09-5
Purity:  99.01%
Target:  

Histone Demethylase

Research Areas:  

Cancer

GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK-J4 hydrochloride is a cell permeable proagent of GSK-J1 [2] .
loading...
    loading...
65
65 Cited Publications
Cat. No.: HY-15648B
CAS No.: 1373423-53-0
Purity:  99.64%
Research Areas:  

Cancer

GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK J4 is a cell permeable proagent of GSK-J1 [2] . GSK-J4 induces endoplasmic reticulum stress-related apoptosis .
loading...
    loading...
61
61 Cited Publications
Cat. No.: HY-50698
CAS No.: 755038-02-9
BI 2536 is a dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively . BI-2536 suppresses IFNB (encoding IFN-β) gene transcription .
loading...
    loading...
57
57 Cited Publications
Cat. No.: HY-100111
CAS No.: 835598-94-2
Purity:  99.48%
Target:  

NADPH Oxidase

Research Areas:  

Metabolic Disease

GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM.
loading...
    loading...
56
56 Cited Publications
Cat. No.: HY-13328
CAS No.: 1224844-38-5
Purity:  99.63%
Synonyms: INK-128; MLN0128; TAK-228
Sapanisertib (INK-128; MLN0128; TAK-228) is an orally active dual mTORC1/mTORC2 inhibitor. Sapanisertib directly and simultaneously inhibits mTORC1/2 activity through competitive binding with ATP, thereby comprehensively blocking downstream processes such as protein and lipid synthesis and cytoskeletal reorganization, consequently suppressing tumor cell proliferation and promoting apoptosis. Sapanisertib is applicable to research on melanoma, ovarian cancer, pulmonary fibrosis, and hematological malignancies [2] .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-10191
CAS No.: 867160-71-2
Purity:  99.87%
Synonyms: OSI-906
Target:  

IGF-1R Insulin Receptor

Research Areas:  

Endocrinology Cancer

Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively .
loading...
    loading...